Clinical Trial Update: Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating rifaximin soluble solid dispersion to delay hepatic encephalopathy decompensation in patients with cirrhosis, sponsored by Bausch Healt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Encephalopathy
• Liver Cirrhosis

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Hepatic Encephalopathy | Phase 3 | Status: ACTIVE_NOT_RECRUITING